Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.

@article{Firbas2010ImmunogenicityAS,
  title={Immunogenicity and safety of different injection routes and schedules of IC41, a Hepatitis C virus (HCV) peptide vaccine.},
  author={Christa Firbas and Thomas Boehm and Vera Buerger and Elisabeth Schuller and Nicolas Sabarth and Bernd Jilma and Christoph S. Klade},
  journal={Vaccine},
  year={2010},
  volume={28 12},
  pages={2397-407}
}
BACKGROUND An effective vaccine would be a significant progress in the management of chronic HCV infections. This study was designed to examine whether different application schedules and injection routes may enhance the immunogenicity of the HCV peptide vaccine IC41. METHODS In this randomized trial 54 healthy subjects received either subcutaneous (s.c.) or intradermal (i.d.) vaccinations weekly (16 injections) or every other week (8 injections). One group additionally received imiquimod, an… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

Similar Papers

Loading similar papers…